Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Solid Tumor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Lung Cancer (4107
)
Breast Cancer (2427
)
Colorectal Cancer (1365
)
Melanoma (1043
)
Sarcoma (668
)
Prostate Cancer (492
)
Bladder Cancer (180
)
Lung Cancer (4107
)
Breast Cancer (2427
)
Colorectal Cancer (1365
)
Melanoma (1043
)
Sarcoma (668
)
Prostate Cancer (492
)
Bladder Cancer (180
)
›
Associations
(16911)
News
Trials
VERI cancer hierarchy
Reset Filters
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
alectinib
Sensitive: A1 - Approval
FDA - 1 week (New A1)
alectinib
Sensitive
:
A1
FDA - 1wk
alectinib
Sensitive: A1 - Approval
FDA - 1 week
alectinib
Sensitive
:
A1
FDA - 1 week - (New A1)
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
PT217
Sensitive: B - Late Trials
PRNewswire - 2 weeks (New B)
PT217
Sensitive
:
B
PRNewswire - 2wk
PT217
Sensitive: B - Late Trials
PRNewswire - 2 weeks
PT217
Sensitive
:
B
PRNewswire - 2 weeks - (New B)
No biomarker
Squamous Cell Carcinoma of Head and Neck
No biomarker
Squamous Cell Carcinoma of Head and Neck
LYT-200
Sensitive: B - Late Trials
Businesswire - 2 weeks (New B)
LYT-200
Sensitive
:
B
Businesswire - 2wk
LYT-200
Sensitive: B - Late Trials
Businesswire - 2 weeks
LYT-200
Sensitive
:
B
Businesswire - 2 weeks - (New B)
HER-2 expression
Solid Tumor
HER-2 expression
Solid Tumor
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
AstraZeneca Press Release - 2 weeks (New A1)
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
AstraZeneca Press Release - 2wk
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
AstraZeneca Press Release - 2 weeks
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
AstraZeneca Press Release - 2 weeks - (New A1)
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
DZD9008
Sensitive: A1 - Approval
PRNewswire - 2 weeks (New B)
DZD9008
Sensitive
:
A1
PRNewswire - 2wk
DZD9008
Sensitive: A1 - Approval
PRNewswire - 2 weeks
DZD9008
Sensitive
:
A1
PRNewswire - 2 weeks - (New B)
BRCA mutation
HER2 Negative Breast Cancer
BRCA mutation
HER2 Negative Breast Cancer
rivoceranib + fluzoparib
Sensitive: B - Late Trials
NAVLIN DAILY - 3 weeks (New B)
rivoceranib + fluzoparib
Sensitive
:
B
NAVLIN DAILY - 3wk
rivoceranib + fluzoparib
Sensitive: B - Late Trials
NAVLIN DAILY - 3 weeks
rivoceranib + fluzoparib
Sensitive
:
B
NAVLIN DAILY - 3 weeks - (New B)
MSI-H/dMMR
Endometrial Cancer
MSI-H/dMMR
Endometrial Cancer
sintilimab + fruquintinib
Sensitive: B - Late Trials
GlobeNewswire - 3 weeks (New B)
sintilimab + fruquintinib
Sensitive
:
B
GlobeNewswire - 3wk
sintilimab + fruquintinib
Sensitive: B - Late Trials
GlobeNewswire - 3 weeks
sintilimab + fruquintinib
Sensitive
:
B
GlobeNewswire - 3 weeks - (New B)
No biomarker
Glioblastoma
No biomarker
Glioblastoma
NOX-A12
Sensitive: B - Late Trials
Businesswire - 3 weeks (New B)
NOX-A12
Sensitive
:
B
Businesswire - 3wk
NOX-A12
Sensitive: B - Late Trials
Businesswire - 3 weeks
NOX-A12
Sensitive
:
B
Businesswire - 3 weeks - (New B)
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
EGFR T790M
Non Small Cell Lung Cancer
EGFR T790M
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
KIT positive
Gastrointestinal Stromal Tumor
KIT positive
Gastrointestinal Stromal Tumor
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
ALK fusion
Non Small Cell Lung Cancer
ALK fusion
Non Small Cell Lung Cancer
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
PDGFRA D842V
Gastrointestinal Stromal Tumor
PDGFRA D842V
Gastrointestinal Stromal Tumor
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
sotorasib
Sensitive: A1 - Approval
sotorasib
Sensitive
:
A1
sotorasib
Sensitive: A1 - Approval
sotorasib
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
MSI-H/dMMR
Solid Tumor
MSI-H/dMMR
Solid Tumor
dostarlimab-gxly
Sensitive: A1 - Approval
dostarlimab-gxly
Sensitive
:
A1
dostarlimab-gxly
Sensitive: A1 - Approval
dostarlimab-gxly
Sensitive
:
A1
No biomarker
Esophageal Adenocarcinoma
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login